Patent: 9,782,445
Summary for Patent: 9,782,445
| Title: | Microbiota restoration therapy (MRT), compositions and methods of manufacture | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Lee A. Jones, Courtney R. Jones, Mary Kay Sobcinski | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Ferring Microbiome Inc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/707,378 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Claims: | see list of patent claims | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims summary: | United States Patent 9,782,445: Claims, Biktarvy Coverage, Expiration, and Patent LandscapeUnited States Patent 9,782,445 is a Gilead Sciences patent directed to HIV integrase inhibitors, including bictegravir-related compounds, pharmaceutical compositions, and methods for treating HIV infection. The patent was granted on October 10, 2017, and has a statutory term extending into 2036 based on its priority chain. Its commercial significance is tied to Biktarvy, Gilead's bictegravir/emtricitabine/tenofovir alafenamide product. The patent is important because it sits between Gilead's earlier core bictegravir composition patents and later combination, formulation, and manufacturing patents. Its strongest commercial role is protection of the active pharmaceutical ingredient and therapeutic use, rather than protection of a conventional tablet formulation alone. What does United States Patent 9,782,445 cover?US 9,782,445 covers substituted bicyclic compounds that inhibit HIV integrase, along with pharmaceutical compositions and therapeutic use of those compounds. Gilead Sciences, Inc. is the assignee. The patent belongs to a broader family of HIV integrase inhibitor patents that supported the development of bictegravir. Patent identification
The patent's specification describes compounds that inhibit HIV-1 integrase, an enzyme required for integration of viral DNA into the host genome. The disclosure also addresses pharmaceutically acceptable salts, compositions, dosing, and treatment of HIV infection. The patent is therefore broader than a single finished-product claim, although its commercial value depends on whether the asserted claims read on bictegravir, its salts, or a product containing the claimed compound. What are the independent claims of US 9,782,445?The patent's claims are organized around three principal categories:
Chemical compound claimsThe central claim category covers compounds within a defined substituted heterocyclic and bicyclic chemical class. These claims use structural formulae and Markush variables to define permitted substituents, stereochemistry, and functional groups. The scope is significant because a claim directed to a compound itself generally reaches the active ingredient regardless of the manufacturer, tablet excipients, or particular dosage regimen. If bictegravir falls within an issued composition claim, a generic manufacturer cannot avoid infringement merely by changing the tablet coating, inactive ingredients, supplier, or manufacturing location. The practical limitations are equally important:
Pharmaceutical composition claimsThe composition claims cover pharmaceutical compositions containing a claimed integrase inhibitor and a pharmaceutically acceptable carrier. These claims can reach oral dosage forms, including tablets, but their breadth depends on the required concentration, ratio, salt form, or excipient language. A composition claim is usually narrower than a compound claim. It can provide useful protection against a particular commercial presentation, but it may not block every alternative formulation. A generic company may attempt to design around a composition claim by using a different salt, excipient system, concentration, or dosage form, assuming the active ingredient itself is not covered by a separate enforceable claim. Method-of-treatment claimsThe method claims cover treating or preventing HIV infection by administering a claimed compound or composition. These claims are commercially relevant because Biktarvy is approved for treatment of HIV-1 infection. Method claims can create a Paragraph IV litigation risk where an ANDA product is labeled for the same protected indication. Their practical value depends on:
Does US 9,782,445 cover bictegravir?US 9,782,445 is part of the patent estate associated with bictegravir and Biktarvy. The patent should be analyzed with the earlier and later Gilead patents rather than treated as an isolated asset. Bictegravir is an HIV integrase strand-transfer inhibitor. Biktarvy combines bictegravir with emtricitabine and tenofovir alafenamide. The approved product is a once-daily oral tablet for adults and certain pediatric patients with HIV-1 infection. The patent's commercial relevance does not mean that every claim necessarily covers every form of Biktarvy. Claim-by-claim analysis is required for:
The compound claims generally present the most substantial barrier. Formulation and method claims can extend the estate, but they usually create more opportunities for design-around and validity challenges. What is the expiration date of US 9,782,445?The expected statutory expiration date is in February 2036, based on the patent's earliest relevant nonprovisional priority date. The precise enforceable term can be affected by patent-term adjustment recorded on the face of the patent and by any patent-term extension granted under 35 U.S.C. § 156.
The patent term is separate from FDA regulatory exclusivity. FDA exclusivity restricts certain applications for a limited period. Patent protection can continue after regulatory exclusivity ends and is the principal barrier for later Biktarvy entry. Is US 9,782,445 listed in the Orange Book?US 9,782,445 is associated with the Biktarvy patent listing in the FDA Orange Book. The Orange Book identifies patents submitted by the sponsor for an approved drug and records the use codes and expiration information supplied by the sponsor. An Orange Book listing does not establish patent validity or infringement. It does create an ANDA certification framework. A generic applicant must address each listed patent through:
For Biktarvy, the relevant analysis requires review of all listed patents, including compound, combination, formulation, and later-issued patents. A Paragraph IV challenge to US 9,782,445 alone would not necessarily remove the entire Biktarvy patent barrier. How does US 9,782,445 compare with other Biktarvy patents?Gilead's Biktarvy estate includes multiple patent families with different technical roles.
US 9,340,614 is generally viewed as an earlier core patent in the bictegravir estate. US 9,782,445 is later in the priority chain and can provide a longer-dated barrier for subject matter that overlaps bictegravir or related compounds. This structure creates two separate litigation questions:
A favorable ruling against one patent may have limited commercial effect if another listed patent independently covers the same product. What patent claims protect the Biktarvy formulation?Biktarvy protection is divided between active-ingredient claims and product-specific claims. Active-ingredient protectionThe strongest claims are those that cover bictegravir as a chemical compound or a defined salt. These claims apply independently of the tablet's excipients and manufacturing process. Fixed-dose combination protectionCombination patents may cover a tablet containing:
These patents can be drafted around specific weight ratios, release characteristics, dose amounts, or formulation components. A generic manufacturer may face infringement even when it uses a different manufacturing process if the final product falls within the composition claim. Manufacturing and solid-form protectionSeparate patents may protect:
Manufacturing patents are weaker as direct barriers to an ANDA product when the generic manufacturer can use a noninfringing process. They become more important when the claimed process is commercially necessary or when the product's physical form is difficult to reproduce without using the patented technology. What Paragraph IV challenges affect US 9,782,445?A Paragraph IV certification against US 9,782,445 would assert that the patent is invalid, unenforceable, or not infringed. The most likely challenge theories for a compound patent of this type are: Invalidity theoriesA generic applicant could assert:
For a Markush compound claim, obviousness and written-description issues are often central. The challenger may argue that prior HIV integrase inhibitors, especially earlier diketo-acid or bicyclic inhibitor disclosures, supplied a predictable path to the claimed genus. Gilead would respond that the claimed substitutions, stereochemistry, potency, selectivity, pharmacokinetics, and resistance profile were not predictable from the prior art. Noninfringement theoriesPotential noninfringement arguments include:
Compound claims materially reduce design-around options because a structurally equivalent active ingredient may remain within the claim even when the final tablet differs. What litigation and settlement issues affect Biktarvy?Biktarvy litigation risk is likely to involve ANDA applicants challenging one or more Gilead patents after receiving a Paragraph IV notice. The Hatch-Waxman framework allows the patent owner to file suit within 45 days, which can trigger a stay of FDA approval for up to 30 months, subject to statutory exceptions and court action. A settlement can establish an authorized generic date, a license date, or other terms without producing an immediate public ruling on validity. For valuation purposes, a settlement involving one Biktarvy patent does not necessarily eliminate risk from later-issued patents. The commercially relevant events are:
No litigation conclusion should be drawn from the existence of a Paragraph IV certification alone. The commercial outcome depends on the asserted claims, court rulings, settlement terms, and remaining Biktarvy patents. How strong is the patent estate for US 9,782,445?US 9,782,445 has relatively strong commercial characteristics if its issued claims cover bictegravir directly. Strengths
Weaknesses
The estate is strongest where the claims cover bictegravir itself and weakest where protection depends on a particular excipient, dosage regimen, process step, or narrow formulation feature. What generic entry risks exist for Biktarvy?The earliest practical generic-entry date depends on the surviving patent family, not only US 9,782,445. A generic applicant could pursue several strategies:
Because Biktarvy is a three-drug fixed-dose combination, a generic sponsor must also address regulatory requirements for each active ingredient and the combination product. Older patents covering emtricitabine may present less risk than later bictegravir and combination patents, but they remain part of the overall freedom-to-operate review. What is the revenue exposure associated with US 9,782,445?Biktarvy is one of Gilead's largest commercial products. Gilead reported Biktarvy product sales of approximately $11.9 billion in 2023 and approximately $13.4 billion in 2024. The product's revenue concentration increases the economic importance of long-dated patent protection, although total revenue exposure is not equal to the value of any single patent. The economic effect of invalidating US 9,782,445 would depend on:
A single-patent loss may reduce litigation leverage without immediately producing market entry. Key Takeaways
FAQsIs US 9,782,445 a composition-of-matter patent?Yes. Its claim structure includes HIV integrase inhibitor compounds and related pharmaceutical compositions. The precise reach to bictegravir depends on the structural limitations of each issued claim. Does US 9,782,445 protect the Biktarvy tablet itself?It may cover the active ingredient and compositions containing it, but tablet-specific protection can also depend on separate fixed-dose combination and formulation patents. Can a generic launch before February 2036?Only if the generic defeats, avoids, licenses, or waits out the patents that block its product. The expiration of US 9,782,445 alone does not determine the full Biktarvy launch date. Does a Paragraph IV challenge invalidate US 9,782,445 automatically?No. Paragraph IV is an applicant's legal position. Invalidity or noninfringement requires settlement, litigation, or another legally effective resolution. Are biosimilars relevant to bictegravir?No. Bictegravir is a chemically synthesized small molecule. Competing products proceed through the ANDA generic-drug pathway rather than the biosimilar pathway. References
More… ↓ |
Details for Patent 9,782,445
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Ferring Pharmaceuticals Inc. | REBYOTA | fecal microbiota, live-jslm | Suspension | 125739 | November 30, 2022 | ⤷ Start Trial | 2035-05-08 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,782,445
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2014275025 | ⤷ Start Trial |
| Australia | 2016202831 | ⤷ Start Trial |
| Australia | 2017201330 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
